James Callaway
Director/Board Member at XENETIC BIOSCIENCES, INC.
Net worth: - $ as of 2024-05-30
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Nickolay Kukekov | M | 49 |
Kalgene Pharmaceuticals, Inc.
Kalgene Pharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Kalgene Pharmaceuticals, Inc. develops and focuses on personalized cancer diagnostics and drugs. It offers drugs for epithelial and thyroid cancers. The firm's oncology programs are aimed at improving clinical and survival outcomes through the use of personalized medicine, with a particular focus on bladder, epithelial and thyroid cancers. It serves the biopharmaceutical, research and development and health industries. The company is headquartered in Kingston, Canada. | 3 years |
James Parslow | M | 59 | 7 years | |
Adam Logal | M | 46 | 7 years | |
Dmitriy Genkin | M | 56 | 5 years | |
Roger Kornberg | M | 76 | 8 years | |
Firdaus Jal Dastoor | M | 72 | 10 years | |
Alexey Vinogradov | M | 54 | 5 years | |
Grigory Borisenko | M | 55 | 5 years | |
Moshe Mizrahy | M | 71 | - | |
Anthony Giovinazzo | M | 67 |
Kalgene Pharmaceuticals, Inc.
Kalgene Pharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Kalgene Pharmaceuticals, Inc. develops and focuses on personalized cancer diagnostics and drugs. It offers drugs for epithelial and thyroid cancers. The firm's oncology programs are aimed at improving clinical and survival outcomes through the use of personalized medicine, with a particular focus on bladder, epithelial and thyroid cancers. It serves the biopharmaceutical, research and development and health industries. The company is headquartered in Kingston, Canada. | 3 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Michael Scott Maguire | M | 61 | 3 years | |
Jeffrey Eisenberg | M | 58 | 8 years | |
John Wahren | M | - |
Cebix, Inc.
Cebix, Inc. Pharmaceuticals: MajorHealth Technology Cebix, Inc. provided treatments for complications of diabetes. It developed Ersatta, a proprietary disease-modifying replacement peptide for the treatment of complications associated with diabetes, including diabetic peripheral neuropathy, autonomic neuropathy, nephropathy, and retinopathy. The company was founded by John Wahren and Lars G. Ekman in 2008 and was headquartered in San Diego, CA. | - |
T. Nathan Yoganathan | M | - |
Kalgene Pharmaceuticals, Inc.
Kalgene Pharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Kalgene Pharmaceuticals, Inc. develops and focuses on personalized cancer diagnostics and drugs. It offers drugs for epithelial and thyroid cancers. The firm's oncology programs are aimed at improving clinical and survival outcomes through the use of personalized medicine, with a particular focus on bladder, epithelial and thyroid cancers. It serves the biopharmaceutical, research and development and health industries. The company is headquartered in Kingston, Canada. | - |
Lars Ekman | M | 74 |
Cebix, Inc.
Cebix, Inc. Pharmaceuticals: MajorHealth Technology Cebix, Inc. provided treatments for complications of diabetes. It developed Ersatta, a proprietary disease-modifying replacement peptide for the treatment of complications associated with diabetes, including diabetic peripheral neuropathy, autonomic neuropathy, nephropathy, and retinopathy. The company was founded by John Wahren and Lars G. Ekman in 2008 and was headquartered in San Diego, CA. | 4 years |
Curtis Lockshin | M | 64 | 10 years | |
Jim Callaway | M | - |
ArmaGen, Inc.
ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | 4 years |
David Kabakoff | M | 76 |
Cebix, Inc.
Cebix, Inc. Pharmaceuticals: MajorHealth Technology Cebix, Inc. provided treatments for complications of diabetes. It developed Ersatta, a proprietary disease-modifying replacement peptide for the treatment of complications associated with diabetes, including diabetic peripheral neuropathy, autonomic neuropathy, nephropathy, and retinopathy. The company was founded by John Wahren and Lars G. Ekman in 2008 and was headquartered in San Diego, CA. | - |
Linda Rubinstein | F | 58 |
ArmaGen, Inc.
ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | 5 years |
Michelle Morgan | F | - |
Cebix, Inc.
Cebix, Inc. Pharmaceuticals: MajorHealth Technology Cebix, Inc. provided treatments for complications of diabetes. It developed Ersatta, a proprietary disease-modifying replacement peptide for the treatment of complications associated with diabetes, including diabetic peripheral neuropathy, autonomic neuropathy, nephropathy, and retinopathy. The company was founded by John Wahren and Lars G. Ekman in 2008 and was headquartered in San Diego, CA. | 3 years |
Steven Schoenfeld | M | - |
ArmaGen, Inc.
ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | 2 years |
Roman Sergeevich Knyazev | M | 44 | 5 years | |
Blaine McKee | M | 59 |
ArmaGen, Inc.
ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | 2 years |
Derek Kelaita | M | - |
ArmaGen, Inc.
ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | 6 years |
Douglas Hunt | M | 59 |
ArmaGen, Inc.
ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | 2 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 22 | 88.00% |
Canada | 3 | 12.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- James Callaway
- Personal Network